Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 4 2Phase 2 2Phase 1/2 2Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2

Conditions

Breast Neoplasms 2760Carcinoma, Non-Small-Cell Lung 2260Prostatic Neoplasms 1425Colorectal Neoplasms 1290Neoplasms 1258Multiple Myeloma 1084Lung Neoplasms 1048Neoplasm Metastasis 994Leukemia, Myeloid, Acute 984Lymphoma 900Melanoma 862Pancreatic Neoplasms 818Ovarian Neoplasms 805Carcinoma, Hepatocellular 782Stomach Neoplasms 753Recurrence 750Leukemia 733Lymphoma, Non-Hodgkin 684Leukemia, Lymphocytic, Chronic, B-Cell 665Lymphoma, Large B-Cell, Diffuse 616Squamous Cell Carcinoma of Head and Neck 615Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Head and Neck Neoplasms 596Brain Neoplasms 592Carcinoma, Renal Cell 586Glioblastoma 572Rectal Neoplasms 563Myelodysplastic Syndromes 522Sarcoma 521Lymphoma, Follicular 516

Interventions

Fentanyl 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Burns × Clear all
NCT00236041 2014-05-09

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
38 enrolled
Classical hematology

Agnosia, Anemia, Sickle Cell, Burns, Neoplasms, Breakthrough Pain

NCT00236093 2014-05-09

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
Classical hematology

Anemia, Sickle Cell, Burns, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡